This announcement is a separate document:
LTR Pharma Ltd: First patients dosed in SPONTAN pivotal study
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.